Skip to content
Clinical Trials – home

Klinisches Forschungszentrum Dr. Hagemann

Research site

Germany Germaniaplatz 8, 45355 Essen, Germany

  • 5 trials recruiting
  • Cardiovascular disorder · Hypertension · Chronic kidney disease
  • Adult patients

About Specializations

Klinisches Forschungszentrum Dr. Hagemann in Essen, Germany specialises in clinical trials of conditions such as Cardiovascular disorder, Hypertension, Chronic kidney disease, Arteriosclerosis, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

The Klinisches Forschungszentrum Dr. Hagemann conducts research aimed at reducing the burden of cardiovascular disease by testing new therapies and preventive strategies. Studies target conditions such as atherosclerosis, heart rhythm disorders, and blood pressure control, with the goal of improving long‑term outcomes for patients at high risk.

  • Atherosclerotic cardiovascular disease
  • Atrial fibrillation
  • Heart failure
  • Hypertension
  • Hypercholesterolemia

This work supports the site’s role as an educational institution while collaborating with commercial partners to bring innovative cardiovascular solutions to the community.

Nutritional and Metabolic Diseases

Researchers at the Hausarztzentrum am Germaniaplatz focus on metabolic health, evaluating interventions that address type 2 diabetes and obesity. The trials aim to improve glycaemic control, reduce body weight, and lower cardiovascular risk associated with metabolic disorders.

  • Type 2 diabetes
  • Obesity
  • Hyperlipidemia
  • Metabolic syndrome
  • Chronic kidney disease

By integrating clinical care with research, the site advances therapeutic options for patients with metabolic conditions.

Respiratory Tract Diseases

The centre investigates acute respiratory infections, including acute bronchitis, to determine the effectiveness of novel and herbal treatments. Objectives include reducing symptom severity and shortening illness duration, thereby enhancing patient recovery.

  • Acute bronchitis
  • Upper respiratory infection
  • Cough and mucus production
  • Symptom severity scores
  • Treatment safety profiles

This research contributes to better management of common respiratory ailments in the local population.

Virus Diseases

Studies at the site evaluate vaccine immunogenicity and protection against influenza, especially in adults over 50 years of age. The trials assess immune response, safety, and the ability of new formulations to prevent viral illness.

  • Influenza vaccine efficacy
  • Immunogenicity in older adults
  • Safety of high‑dose formulations
  • Cellular immune response
  • Prevention of virus‑related complications

These efforts align with public health goals to reduce seasonal flu impact and support the site’s educational mission.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Germaniaplatz 845355 EssenGermany
Recruiting now
5 trials
Conditions studied
13

More sites in EssenGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

12 clinical trials

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Study of YMI024 to Reduce Inflammation in Adults with Stable Coronary Artery Disease and Elevated hsCRP

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Arteriosclerosis

Not recruiting

Study on the Effect of Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease Not Adequately Managed by Current Lipid-Lowering Treatments

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obicetrapib
  • Sponsor:NewAmsterdam Pharma B.V.

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Influenza

Not recruiting

Study on the Safety and Immune Response of aQIVc HD Vaccine Compared to a Drug Combination for Adults 50 Years and Older at Risk of Flu Complications

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/(H3N2)-LIKE VIRUS ANTIGEN
  • Sponsor:Seqirus UK Limited

Bronchitis

Not recruiting

Study on the Effectiveness of Thyme Herb Extract, Primrose Root Tincture, and Ivy Leaf Extract for Patients with Acute Bronchitis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dry Extract Of Hederae Folium (5-7.5:1), Extraction Solvent: Ethanol 30% (M/M)
  • Sponsor:Engelhard Arzneimittel GmbH & Co. KG

Hypercholesterolaemia

Not recruiting

Study Comparing Inclisiran and Bempedoic Acid for Lowering LDL Cholesterol in Patients with Atherosclerotic Cardiovascular Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma GmbH

Study on the Effectiveness of Enlicitide Chloride in Reducing Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Sharp & Dohme LLC
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.